Geron Co. (NASDAQ:GERN) Receives Average Recommendation of “Buy” from Brokerages

Shares of Geron Co. (NASDAQ:GERN) have earned a consensus rating of “Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $7.05.

Several research firms have commented on GERN. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Geron in a report on Friday, August 9th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Geron in a report on Thursday, August 8th. StockNews.com raised Geron to a “sell” rating in a report on Monday, August 5th. Leerink Partnrs raised Geron to a “strong-buy” rating in a report on Monday, September 9th. Finally, HC Wainwright assumed coverage on Geron in a report on Tuesday. They issued a “buy” rating and a $8.00 target price for the company.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. National Bank of Canada FI boosted its position in Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 6,000 shares during the last quarter. Crewe Advisors LLC boosted its position in Geron by 870.0% in the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC bought a new position in Geron in the 1st quarter valued at $34,000. American Trust bought a new position in shares of Geron in the 1st quarter worth $38,000. Finally, Rovin Capital UT ADV bought a new position in shares of Geron in the 3rd quarter worth $62,000. 73.71% of the stock is currently owned by institutional investors.

Geron Price Performance

NASDAQ GERN opened at $4.27 on Thursday. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. The stock has a market capitalization of $2.57 billion, a PE ratio of -11.86 and a beta of 0.52. The stock has a 50-day simple moving average of $4.33 and a 200 day simple moving average of $4.30.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The company’s revenue for the quarter was up 2941.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) EPS. Research analysts anticipate that Geron will post -0.34 EPS for the current year.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.